Drug derived from curcumin may help treat stroke

March, 2011

More evidence for the value of the curry spice curcumin comes from animal studies indicating a curcumin-derived drug may help treat stroke.

A new molecular compound derived from curcumin (found in turmeric) holds promise for treating brain damage caused by stroke. Turmeric has a long history of use in Ayurvedic and Chinese traditional medicine. However, curcumin has several important drawbacks as far as treating stroke is concerned — mainly because it can’t cross the blood-brain barrier. The new compound can.

In rabbit experiments, the drug was effective when administered up to an hour after stroke, which correlates with about three hours in humans. This is the same time frame for which tPA — the only drug currently approved for ischemic stroke — is currently approved.

The new drug is expected to move to human clinical trials soon.

Reference: 

Paul A. Lapchak presented these findings at the American Heart Association International Stroke Conference in Los Angeles on February. 9.

Related News

Data from 6257 older adults (aged 55-90) evaluated from 2005-2012 has revealed that concerns about memory should be taken seriously, with subjective complaints associated with a doubled risk of developing mild cognitive impairment or dementia, and subjective complaints supported by a loved on

Analysis of mitochondrial DNA (mtDNA) in the cerebrospinal fluid has found that both symptomatic Alzheimer’s patients and asymptomatic patients at risk of A

Comparison of the EEGs of 27 healthy older adults, 27 individuals with mild Alzheimer's and 22 individuals with moderate cases of Alzheimer’s, has found statistically significant differences across the three groups, using an algorithm that dissects brain waves of varying frequencies.

Data from two longitudinal studies of older adults (a nationally representative sample of older adults, and the Alzheimer’s Disease Neuroimaging Initiative) has found that a brief cognitive test can distinguish memory decline associated with healthy aging from more serious memory disorders, year

Analysis of 40 spinal marrow samples, 20 of which belonged to Alzheimer’s patients, has identified six

Data from 848 adults of all ages has found that brain volume in the default mode network declined in both healthy and pathological aging, but the greatest decline occurred in Alzheimer’s patients and in those who progressed from mild cognitive impairment to Alzheimer’s disease.

New research supports the classification system for preclinical Alzheimer’s proposed two years ago. The classification system divides preclinical Alzheimer's into three stages:

Initial findings from an analysis of cerebrospinal fluid taken between 1995 and 2005 from 265 middle-aged healthy volunteers, of whom 75% had a close family m

Cognitive testing for dementia has a problem in that low scores on some tests may simply reflect a person's weakness in some cognitive areas, or the presence of a relatively benign form of mild cognitive impairment (one that is not going to progress to dementia).

A French study has predicted with 90% accuracy which patients with mild cognitive impairment would receive a clinical diagnosis of Alzheimer's disease within the following two years.

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news
Error | About memory

Error

The website encountered an unexpected error. Please try again later.